Jessica Sharpe

Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers link.springer.com/article/10.100… In this large real-world study of 415 patients with early-stage or locally advanced triple-negative #BreastCancer (TNBC) treated with the KEYNOTE-522 regimen (pembrolizumab plus chemotherapy), researchers found a pathologic complete response (pCR) rate of 52%, which was lower than reported in clinical trials. Adverse events were frequent—88% experienced AEs and 38% had grade 3 or higher toxicity—leading to early pembrolizumab discontinuation in nearly one-third of patients. Hospitalization occurred in 26% of cases, with obese patients facing significantly higher hospitalization rates. Importantly, no racial disparities were observed in AE, pCR, or hospitalization outcomes. @jesmezz @Ekaterinapros94 @mateo_montalvo4 @DrKarineTawagi @quirogad

⭐️My friend @CathyEngMD and I would like to THANK our friends, colleagues, attendees, MEC team, and industry sponsors for making our MLS Nashville 2025 ASCO review a FUN educational event. #Reels David R. Spigel, MD @DavidRSpigel Christine M. Lovly, MD, PhD, FASCO @christine_lovly Luis E Raez @LuisRaezMD Joyce O'Shaughnessy @BCJoyceO Sonya Reid MD @Sonyareid07 Jessica Sharpe MD @jesmezz Alan Tan, MD @alantanmd Benjamin Garmezy @BGarmezy Daniel Vaena @west_cancer Ronak Mistry @rmistry91 Katherine Walsh MD @Kathy_WalshMD Muhamed Baljevic MD @MMBaljevicMD Christopher Cann MD @ChrisCannMD Mehmet Akce MD @MehmetAkce2 Anna Uhelski MD @ACRUhelski Matthew Kurian, MD @MatthewKurianMD

Closed the @mecmededucation post-ASCO updates with Co-Chair @CParkMD. GREAT insightful sessions in #breastcancer and #lungcancer 🫁. 🤩 @christine_lovly + Drs. Sonya Reid + Jessica Sharpe @VUMCDiscoveries and Drs. Joyce O’Shaunessy + David Spigel, @SarahCannonDocs and our #APPs in attendance. #CancerResearch #cancer

I always learn something new from @Sonyareid07 @VUMC_Cancer re: #breastcancer #cancer #ASCO24 update #cancerresearch. @mecmededucation @jordanberlin5 @benhopark

Great to have @OncBrothers participate and now have Dr. Rahul Gosain @WilmotCancer lead the #breastcancer panel with @wadavidal @Sonyareid07 and @jesmezz. #cancer #cancerresearch @mecmededucation @CParkMD

When the immunotherapy kicks in and the T-cells finally recognize the cancer as a threat twitter.com/Yoda4ever/stat…

⭐️THRILLED to host this meeting w/ my good friend Dr. Cathy Eng in beautiful Nashville. Join us as we have the LEADING thought leaders discuss the latest data including a special appearance by the @OncBrothers Register here👇 web.cvent.com/event/c61fd6dd… @CathyEngMD @DavidRSpigel @christine_lovly @jpmd901 @MMBaljevicMD @MVillaume @ChrisCannMD @katy_beckermann @BGarmezy @jordanberlin5 @jesmezz @Sonyareid07 @wadavidal

Great final morning at #SABCS23’s career development day. Loved these “life lessons” from Dr. Mittendorf

Fantastic final discussion at #SABCS23 about what to do in the trenches Monday morning based on what we learned this week. Loved hearing from some amazing med onc, rad onc, and surg onc physicians as well as Leslie, a patient advocate living with MBC for 11 years.

Few thoughts on INAVO120 data presented today @SABCSSanAntonio. #bscm @OncoAlert @PIK3CApathbreak 1. This is a potent triplet combination with a doubling of PFS (delta PFS 8 mo). OS trending in positive direction.

Abemaciclib MonarchE benefited patients across intrinsic molecular subtypes, in both high- and low-risk scores using inferred Oncotype MYC amplified tumors may represent a group who derive less benefit, but further analysis needed. #SABCS23 @OncoAlert

The #OncoAlertTopTweet 🚨Day 3⃣ #SABCS23 Tweet by Our @OncoAlert faculty @DrSGraff 🇺🇸 Presentation by our own @matteolambe 🇮🇹 No detrimental prognostic effect of pregnancy after BC in BRCA carriers🧬 Link jamanetwork.com/journals/jama/…

Really loved this acknowledgment for all of the patients that participated in TROPION-Breast01. #SABCS23

And finally, a really great talk on iRAE by @VUMCHemOnc’s very own Dr. Johnson. There was more, but that’s all for tonight. Excited for day 3 tomorrow!

No difference in PFS, but small and improved PFS in pembro+olaparib group in BRCAm patients. - MONARCH3 final OS results: 66.8 months vs 53.7 months (although not statistically significant).

Some learning points from #SABCS23 day 2: - CheckMate 7FL: improved pCR with nivo added to neoadjuvant chemo in high-risk ER+HER- BC (greater benefit in PD-L1+ tumors). Awaiting EFS data. -KEYNOTE-756: pembro+neoadjuvant chemo improved pCR in ER+HER2- BC

Great educational session on toxicity management—CDK4/6i toxicity from Dr. Mayer

And then an announcement on breaking news that will be announced this week 🎉

So excited for this lineup! #SABCS23